Jacobs & Co. CA Has $3.04 Million Position in Celgene Co. (CELG)

Jacobs & Co. CA lifted its holdings in Celgene Co. (NASDAQ:CELG) by 11.0% in the 4th quarter, Holdings Channel reports. The firm owned 29,509 shares of the biopharmaceutical company’s stock after buying an additional 2,925 shares during the quarter. Jacobs & Co. CA’s holdings in Celgene were worth $3,043,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the stock. Fort Pitt Capital Group LLC lifted its stake in shares of Celgene by 0.6% in the 2nd quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock valued at $250,000 after purchasing an additional 11 shares during the last quarter. Linscomb & Williams Inc. lifted its stake in shares of Celgene by 1.0% in the 2nd quarter. Linscomb & Williams Inc. now owns 3,813 shares of the biopharmaceutical company’s stock valued at $495,000 after purchasing an additional 36 shares during the last quarter. RNC Capital Management LLC lifted its stake in shares of Celgene by 0.9% in the 2nd quarter. RNC Capital Management LLC now owns 5,270 shares of the biopharmaceutical company’s stock valued at $684,000 after purchasing an additional 45 shares during the last quarter. Raab & Moskowitz Asset Management LLC lifted its stake in shares of Celgene by 1.2% in the 2nd quarter. Raab & Moskowitz Asset Management LLC now owns 7,701 shares of the biopharmaceutical company’s stock valued at $1,003,000 after purchasing an additional 89 shares during the last quarter. Finally, Cetera Investment Advisers lifted its stake in shares of Celgene by 5.8% in the 2nd quarter. Cetera Investment Advisers now owns 2,191 shares of the biopharmaceutical company’s stock valued at $284,000 after purchasing an additional 120 shares during the last quarter. 78.63% of the stock is owned by institutional investors and hedge funds.

Several research analysts recently commented on CELG shares. Atlantic Securities upgraded shares of Celgene from a “neutral” rating to an “overweight” rating in a report on Friday, December 8th. Cantor Fitzgerald set a $112.00 target price on shares of Celgene and gave the stock a “hold” rating in a report on Monday, December 11th. Piper Jaffray reiterated a “hold” rating on shares of Celgene in a report on Sunday, December 10th. BidaskClub upgraded shares of Celgene from a “sell” rating to a “hold” rating in a report on Tuesday, December 12th. Finally, Deutsche Bank started coverage on shares of Celgene in a report on Tuesday, December 12th. They issued a “hold” rating and a $114.00 target price on the stock. Three equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $127.68.

In other Celgene news, Director Ernest Mario sold 13,370 shares of the business’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $94.49, for a total value of $1,263,331.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director James J. Loughlin sold 9,250 shares of the business’s stock in a transaction dated Monday, March 12th. The shares were sold at an average price of $92.01, for a total transaction of $851,092.50. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 41,120 shares of company stock worth $3,879,509. Company insiders own 0.95% of the company’s stock.

NASDAQ CELG opened at $89.21 on Friday. The stock has a market capitalization of $67,101.59, a P/E ratio of 13.04, a price-to-earnings-growth ratio of 0.60 and a beta of 1.58. Celgene Co. has a twelve month low of $84.95 and a twelve month high of $147.17. The company has a current ratio of 4.99, a quick ratio of 4.80 and a debt-to-equity ratio of 2.29.

Celgene (NASDAQ:CELG) last posted its earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.78 by $0.09. The business had revenue of $3.48 billion for the quarter, compared to analysts’ expectations of $3.46 billion. Celgene had a net margin of 22.38% and a return on equity of 67.50%. The firm’s revenue for the quarter was up 16.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.61 earnings per share. research analysts anticipate that Celgene Co. will post 7.66 earnings per share for the current fiscal year.

Celgene declared that its board has approved a share buyback plan on Wednesday, February 14th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

TRADEMARK VIOLATION NOTICE: “Jacobs & Co. CA Has $3.04 Million Position in Celgene Co. (CELG)” was posted by WKRB News and is the property of of WKRB News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://www.wkrb13.com/2018/03/31/jacobs-co-ca-has-3-04-million-position-in-celgene-co-celg.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply